Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $9.16, for a total value of $91,600.00. Following the transaction, the chief executive officer now directly owns 522,143 shares of the company’s stock, valued at approximately $4,782,829.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Karyopharm Therapeutics Inc (KPTI) opened at $10.52 on Friday. The stock has a market capitalization of $496.34, a PE ratio of -3.95 and a beta of 4.08. Karyopharm Therapeutics Inc has a one year low of $7.48 and a one year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. sell-side analysts anticipate that Karyopharm Therapeutics Inc will post -2.58 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth about $136,000. Voya Investment Management LLC raised its stake in shares of Karyopharm Therapeutics by 42.1% during the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $202,000. State of Wisconsin Investment Board purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $235,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Karyopharm Therapeutics by 26.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after purchasing an additional 5,586 shares in the last quarter. 60.92% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have recently commented on KPTI. Royal Bank of Canada reaffirmed a “buy” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, October 18th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Jefferies Group reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, October 13th. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, Zacks Investment Research downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Karyopharm Therapeutics presently has a consensus rating of “Buy” and an average target price of $17.33.
WARNING: “Insider Selling: Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Sells 10,000 Shares of Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/12/karyopharm-therapeutics-inc-kpti-ceo-sells-91600-00-in-stock.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.